Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALADON: Bevacizumab + Docetaxel as Neoadjuvant Chemotherapy in Primary Breast Cancer
NCT01690325Phase 2Terminated
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Sep 2012
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in breast cancer, sponsored by Westdeutsche Studiengruppe. Started Sep 2012; status: terminated.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01690325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01690325.